Technology

Neoleukin Therapeutics

$13.34
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.34 (+2.62%) Today
$0.00 (0.00%) As of 11:02 AM UTC after-hours

Why Robinhood?

You can buy or sell NLTX and other stocks, options, and ETFs commission-free!

About NLTX

Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA. The listed name for NLTX is Neoleukin Therapeutics, Inc. Common Stock.

CEO
Jonathan G. Drachman
Employees
36
Headquarters
Seattle, Washington
Founded
2003
Market Cap
585.23M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
412.75K
High Today
$13.39
Low Today
$12.80
Open Price
$12.86
Volume
251.64K
52 Week High
$18.13
52 Week Low
$5.81

Collections

NLTX Earnings

-$0.44
-$0.29
-$0.15
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 11, Pre-Market

You May Also Like

USMC
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure